Skip to main content

Table 1 Patients characteristics

From: Cytomegalovirus reactivation and its clinical impact in patients with solid tumors

Gender

Age

Tumor entity

TX setting

Tumor therapy

CMV copies/mL

Assay (specimen)

Kind of co-infection

CMV therapy

Outcome

f

59

Breast

adjuvant

no

235

blood

no

no

alive

m

59

SCLC

palliative

CTX

132

blood

no

no

alive

f

79

SCLC

palliative

CTX

34

blood

HSV-esophagitis

no

alive

f

93

Breast

palliative

anti-hormonal

120

blood

no

no

alive

m

70

SCC

adjuvant

CTX/RTX

62

blood

no

no

alive

m

52

SCC

palliative

CTX/RTX

7,650

blood

no

no

alive

f

53

Breast

palliative

CTX

8,000

blood

no

no

alive

m

76

CUP

palliative

CTX

129

blood

no

no

alive

f

63

Pancreas

palliative

CTX

34

blood

no

no

alive

m

65

Pancreas

palliative

CTX

3,409

blood

EBV, candida, pseudomonas

no

death

m

85

Esophagus

palliative

CTX

4,500

blood

no

gancyclovir

alive

f

65

Breast/Lung

adjuvant

CTX

14,000

blood & BAL

EBV, HSV

gancyclovir

alive

m

67

CUP

palliative

CTX

18,000

blood

no

gancyclovir

alive

f

72

CUP

palliative

CTX

8434

blood

no

gancyclovir

alive

f

63

Breast

adjuvant

CTX

476

blood

no

gancyclovir

alive

f

81

Pancreas

palliative

CTX

6,000

blood

Aspergillus, EBV, candida

gancyclovir

death

f

69

Breast

adjuvant

CTX

6,810

blood & BAL

Aspergillus, EBV

gancyclovir

death

  1. BAL bronchioloalveolar lavage, CMV cytomegalovirus, CTX chemotherapy, CUP carcinoma of unknown origin, EBV Epstein-Barr virus, HSV herpes-simplex virus, RTX radiotherapy, SCC squamous cell cancer, SCLC small cell lung cancer